In another phase IB clinical study, autologous MoDCs cultured in GM-CSF, IL-4, and autologous plasma and co-electroporated with mRNA molecules encoding melanoma-associated antigens (MAAs) including MAGE-A3, MAGE-C2, tyrosinase and gp100, linked to an HLA class II targeting signal were injected intradermally and intravenously into pretreated patients with unresectable, histologically confirmed stage 3 or 4 melanoma, who did not receive any other cancer-related treatment at the time of the trial. The gene discussed is PMEL; the disease is melanoma.